Targeting the macrophage population to reprogram or enhance TAMs into an M1-polarized, CXCL10-secreting state offers a promising new therapeutic approach, particularly for ovarian cancer subtypes like clear cell carcinoma (CCC), which are often marked by immune exclusion and poor prognosis. The gene discussed is CXCL10; the disease is ovarian carcinoma.